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Epithelial-Mesenchymal Transition (EMT), is a highly regulated process that is involved in wound 
healing and cancer progression. Previous research has shown that when the healing process is 
dysregulated, EMT can play a role in cancer metastasis. Previous work has shown that EMSY acts 
as an oncogene in breast and ovarian cancer, while the role that EMSY plays during EMT in lung 
cancer and the epithelial integrity of lung cells is unknown. This will be addressed in this research 
project.          
Objective 
To Determine the expression of C11orf30 and the cellular localization of EMSY in response to EMT 
signals (TGFb1, scratch). Develop a model for the role of EMSY in lung epithelial homeostasis and 
EMT.  
Methods & Results 
A non-cancerous epithelial cell line, BEAS-2B, as well as a cancerous lung epithelial cell line, A549, 
were treated for 24 hours with TGF-β1 to induce EMT. Quantitative PCR results showed that during 
EMT progression, the expression of CDH1 was down-regulated, whereas CDH2 gene expression 
was increased in bot BEAS-2B and A549 cells. These are both early EMT makers and indicated that 
early EMT has occurred. CDH1 and CDH2 play a vital role in maintaining epithelial integrity, and 
dysregulation of these genes could lead to the cells taking on a mesenchymal phenotype.  
Preliminary results indicated that in untreated BEAS-2B cells, EMSY is located in the nucleus of the 
cells, where it is able to regulate the gene expression of CDH1. Results also showed that EMSY 
relocated into the cytoplasm during TGF- β1 induced EMT, in BEAS-2B cells. It was found that the 
cellular relocation of EMSY, during EMT in BEAS-2B, cells was controlled by TGF-β1 and 
scratches. QPCR analyses showed that CDH1 gene expression increased in 1% FCS relative to 10% 
FCS. ChIP analyses revealed that during 1% FCS EMSY binds to the promoter of CDH1. Therefore, 
it showed that in BEAS2B cells, increased binding of EMSY to CDH1 promoter is correlated with 
increased CDH1 expression, suggesting EMSY activates CDH1.  
Conclusion       
It was shown that during migration in BEAS-2B cells, EMSY relocates into the nucleus of the cells. 
Since EMSY is nuclear in untreated BEAS-2B cells it highlights that EMSY must regulate the 
transcription of genes involved in migration. TGF-β1 induced EMT, in BEAS-2B cells, caused 
EMSY to be exported out of the nucleus of cells. Therefore, if EMSY is to have a role in EMT, it 
must involve cellular redistribution. Knowing how EMSY regulates the EMT process in lung cancer 
cells, expands the data on the functions of EMSY in various cancers. This could lead to the 






Lung cancer is one of the most prevalent cancers in Australia, with the data showing that lung cancer 
is the most common cause of cancer-related death for people between the ages of 45-64 (Morampudi 
et al., 2017). Lung carcinoma is at its most dangerous when it starts to metastasise from its primary 
tumor location to form a secondary tumor at a distal site. During this event, the organisation of the 
epithelial layer of the lung is dysregulated. The dysregulation of the organisation and structure of the 
epithelial barrier leads to invasion and metastasis and this is a hallmark of cancer (Imielinski et al., 
2012).    
The lung epithelium is composed of squamous, cuboidal, and columnar cells that are joined 
to one another through tight junctions and adherent junctions. Squamous cells are thin and 
flat, whereas cuboidal cells are cubical or round shaped. Columnar cells are elongated and 
cylindrical shaped. A simple epithelium is comprised of a single layer of cells that are 
attached to a basement membrane. A stratified epithelium is composed of two or more cells 
layers (Bragulla and Homberger, 2009). The bronchiolar tubules of the lungs are lined 
primarily by pseudostratified columnar epithelium whereas as the alveolar ducts and 
alveoli are mainly made up of simple squamous epithelium (Mucenski et al., 2003). These layers of 
the epithelium link together to form an epithelial barrier. The barrier protects the lung from external 
environmental factors, such as airborne pathogens, but it also plays a role in absorption, filtration and 
excretion (Frizzell et al., 1986).  
Adherens and tight junctions provide adhesive contact between adjacent lung epithelial cells. 
Adherens junctions stabilize cell to cell adhesion while regulating the actin cytoskeleton, 
intracellular signaling and transcriptional regulation of lung epithelial cells (Hartsock and 
Nelson, 2008). Adherens junctions consists of transmembrane glycoproteins such as E-cadherin 
(epithelial cadherin), N-cadherin (neural cadherin), and the proteins β-catenin and α-catenin that 
belong to the catenin family. (Brune et al., 2015). During the early stages of development, E-cadherin 
is highly expressed. However, during the later stages of development, in particular when the neural 
plate is formed, N-cadherin is expressed and there is a decrease in E-cadherin (Tepass et al., 2000). 
To some extent N-cadherin promotes cell-cell adhesion, however its central role is to promote cell 
migration (Shih and Yamada, 2012). E-cadherin is the main transmembrane protein of the adherens 
junction and its main role is to bind and localize cytoplasmic proteins known as catenins. Catenins 
bind the cadherin proteins to the actin cytoskeleton. A decrease in E-cadherin expression disrupts the 
regulation and binding of α-catenin and β-catenin. The α-catenin protein binds to the C-terminal 
cytoplasmic domain of E-cadherin. The regulation of β-catenin is critical as its main role is to bind 
to the transcription factor Tcf/Lef and facilitate the transcription of genes involved in cell 
proliferation. The binding of β-catenin to E-cadherin occurs through the activation of the Wnt 
signaling pathway. The E-Cadherin/ β-catenin complex plays a vital role in maintaining epithelial 
integrity.  Disrupting the E-Cadherin/ β-catenin complex affects the adhesive forces between cells, 
as well as the Wnt-signaling pathway. Disruption of this complex can lead to various human 
malignancies and inflammatory disorders (Tian et al., 2011). The catenins are an example of how the 
organisation of the epithelial barrier is maintained through direct links to gene transcription in the 
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nucleus (Figure 1). Understanding the transcriptional regulation of epithelial cell migration and 
invasion is an important area of research in terms of understanding cancer.  
 
Figure 1.1: Diagram showing structure of lung epithelium (basement membrane, adherens 
junctions, tight junctions). The lung epithelium is composed of cells that are attached to 
one another through tight junctions and adherens junctions (taken from Oldenburger et al., 2012). 
Claudin and occluding binds to ZO1,2 and 3 which attaches to action filaments and make up the tight 
junction in cells. E-cadherin binds to β-and α-catenin which binds to actin filaments. This protein 
complex makes up the adherens junction in lung cells.   
2.1. Identification of C11orf30 (EMSY) as a possible regulator of the epithelial barrier 
Genome wide association studies (GWAS) can be used to identify genes that contribute to epithelial 
homeostasis. GWAS identify genes involved in human diseases by searching the human genome for 
small genetic variants, called single nucleotide polymorphisms (SNPs). Alleles of these SNPs that 
occur more frequently in people with certain diseases are said to be associated with that disease. 
Researchers use these GWAS to identify alleles that contribute to a person’s risk of developing 
certain diseases. Independent GWAS identified two SNPs (rs7130588 and rs2155219) between the 
genes C11orf30 and LRRC32, that have a strong association with inflammatory diseases such as 
asthma and atopic dermatitis (Esparza-Gordillo et al., 2009, Bønnelykke et al., 2013). The SNP 
rs2155219 has a genome-wide significance p value of 8.17 x 10-9 and an odds ratio of 1.36, while 
rs7130588 has a significant p value of 5.81 x 10-7 and an odd ratio of 1.29 (Weidinger et al., 2013).  
This shows that individuals who have inherited the risk alleles for these two SNPs have a small but 
significantly increased risk of developing asthma or atopic dermatitis. The link between C11orf30 
and genetic association with inflammatory epithelial diseases such as asthma and dermatitis, suggests 
C11orf30 is an important locus in the context of epithelial diseases. 
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GWAS have identified four SNPs located between C11orf30 and LRRC32 (rs7130588, rs2508746, 
rs10899234, and rs6592657) that are located in a region that includes a possible enhancer. This region 
is associated with specific epigenetic marks, such as Histone 3 mono-methylation of lysine 4 
(H3K4Me1) and acetylation of lysine 27 that identify active enhancers. The main function of an 
enhancer is to regulate transcription. Enhancers are regulatory DNA sequences that contain multiple 
binding sites for various transcription factors. These transcription factors regulate tissue-specific and 
inducible transcription of associated genes (Ong and Corces, 2011).  This putative enhancer might 
regulate C11orf30 expression and epithelial integrity.   
Figure 1.2: In silico data using ChIP and SNPs to illustrate in a region between C11orf30 and 
LRRC32 that may be a possible enhancer. The locus is located in a region marked with epigenetic 
markers such as H3k4me3 and H3k4me1. High methyl levels of H3k4me3 and H3k4me1indicated 
active enhancers.   
C11orf30 encodes the protein EMSY that is regulated by the phosphatidylinositol-3-kinase (PI3K)/Akt 
pathway during viral infections. Upon a viral infection, the PI3K/Akt pathway is activated, viral 
replication is suppressed through the increased expression of Interferon Stimulatory Genes (ISG). 
Activation of the PI3K/Akt pathway phosphorylates EMSY, resulting in export of EMSY from the 
nucleus.  Chemical inhibition the PI3K/Akt pathway with the inhibitor LY294002 inhibited 
phosphorylation of EMSY and led to the increased viral replication (Ezell et al., 2012). Based on 
this, it is proposed that activation of the PI3K pathway de-represses expression of a set of ISGs 
through export of EMSY from the nucleus. Additional evidence shows that the PI3K/Akt pathway is 
active during breast and ovarian cancer (Tian et al., 2015b).  
These observations indicated that the cellular localization of EMSY is regulated by the PI3K/Akt 
pathway as part of a broader anti-viral immune response. However, given that PI3K/Akt signaling is 
activated during wound healing EMT and cancer progression (Ezell et al., 2012, Tian et al., 2015b) 





The PI3K/Akt signaling pathway is involved in TGF-β1-induced EMT, and inhibition of the 
PI3K/Akt pathway suppresses EMT in tumor cells (Bakin et al., 2000). TGF-β is a cytokine that 
activates a signaling pathway that drives cancer progression through its immunosuppressive and pro-
angiogenic potential, but more recently has been identified as an inducer of EMT in various cancer 
cell lines (Xu et al., 2009). The process by which TGF-β1 is able to activate the PI3K/Akt pathway 
is still unclear. A study has shown that TGF-β1 activates the PI3K signaling pathway and 
phosphorylates Akt, which in turn phosphorylates Twist and promotes the activation of TGF-β2 
transcription and the TGF-β receptors (Xu et al., 2009). Twist is an EMT-associated transcription 
regulatory protein that regulates EMT in cells (Serrano-Gomez et al., 2016). The activation of TGF-
β2 transcription and the TGF-β receptors leads to the down-regulation of epithelial markers and the 
up-regulation of mesenchymal markers, thus leading to cells losing the cell to cell contact and tumor 
aggressiveness. Moreover, when TGF-β1 activates the PI3K/Akt signaling pathway during EMT, it 
causes EMT-related adhesion and tight junction disruption, delocalizing E-cadherin, Zo-1 and 
integrin β1 from the tight junctions, and causing the cell to acquire a spinal motile morphology 
(Bakin et al., 2000). There are 3 Akt kinase isoforms: Akt1, Akt2 and Akt3, and each have a distinct 
function when activated. Akt2 is a crucial factor in the PI3K/Akt signaling pathway, as it regulates cell 
proliferation and differentiation (Xu et al., 2015). Silencing of Akt2 during TGF-β1 induced EMT is 
correlated with a decrease in the EMT phenotype and an increase in E-cadherin expression. When 
activated, Akt2 phosphorylates heterogeneous nuclear ribonucleoprotein E1 (hnRNPE1), which promotes the 
activation of EMT-inducing transcription factors such as Snail and Zeb (Lamouille et al., 2014). In addition, 
the Akt kinase induces the transcription of Snail1 through the activation of nuclear factor B (NF-κB), 
inducing EMT in squamous cell carcinoma cells (Gonzalez and Medici, 2014). Therefore, TGF-β1 induced 
EMT is in part due to the activation of the PI3K/Akt pathway that acts on EMT transcription factors. 
Whether the cellular localization of EMSY is regulated by the PI3K/Akt pathway during TGF-β1 
induced EMT in lung epithelial cells is a key research question in this thesis.     
2.2. EMSY suppresses and activates genes involved in cancer progression and viral 
replication    
Although a recent study suggested that the immune-regulatory gene LRRC32 and not EMSY 
contributes to inflammatory epithelial diseases (Manz et al., 2016) , there is evidence from cancer 
studies that supports a role for EMSY in maintaining epithelial barrier integrity. DNA amplification 
at band 11q13 of chromosome 11 is common in breast cancer (Hughes-Davies et al., 2003)and the 
genes CCND1 and C11orf30 are thought to be the key genes associated with cancerous changes 
associated with amplification of this locus. In one study, a total of 940 primary breast tumors and 39 
breast cancer cell lines were investigated and the real-time QPCR results showed that C11orf30 
overexpression is positively correlated with DNA amplification in both primary tumors and cell lines. 
Both univariate and multivariate analyses revealed that over-expression of C11orf30 is correlated 
with shortened disease-free survival (Rodriguez et al., 2004).   
Previous studies show that EMSY interacts with the breast and ovarian cancer-associated protein 
BRCA2 and may play a role in chromatin remodeling (Devilee, 2004).   The function of EMSY is 
due to EMSY containing an ENT domain (Chavali et al., 2005). The ENT domain of EMSY binds 




and impairs chromatin stability. Disruption of BRCA2 function in breast epithelial cells leads to the 
loss of maintenance of chromosome stability causing genetic changes in the breast epithelium, and 
the development of breast cancer (Hughes-Davies et al., 2003). 
Other evidence indicates that EMSY acts as an oncogene through repression of the gene expression 
of micro-RNA 31 (Vire et al., 2014). MiR-31 is a key regulator of breast cancer metastasis. The 
mechanism by which EMSY represses the transcription of miR-31 is through its interaction with the 
ETS-1 transcription factor. ETS-1 binds directly to the miR-31 promoter and recruits EMSY and the 
H3K4me3 demethylase KDM5B, repressing the expression of miR-31. Loss of miR-31 significantly 
enhances the invasion and migration capacity of MCF-7 cells, indicating that EMSY acts as an 
oncogene in breast and ovarian cancer (Vire et al., 2014).  
The literature has shown that EMSY is a transcription repressor and can be classed as an oncogene 
due to being over-expressed in breast cancer. However more recently Varier et al (2016), 
demonstrated that EMSY activates gene transcription by directly interacting with the promoters of 
target genes to stimulate cell proliferation. The study found that the DNA binding protein ZNF131 
recruits EMSY and KDM5A to the promoter site of H3K4me3-marked, actively transcribed genes. 
When EMSY expression was knocked down, there was reduced expression of the genes that EMSY 
and KDM5A bind. When EMSY was re-expressed it resulted in upregulation EMSY/KDM5A target 
genes (Varier et al., 2016b).   
Previous literature has shown that EMSY binds to KDM5A and KDM5B. KDM5A and KDM5B 
have opposing functions. KDM5A promotes differentiation whereas KDM5B promotes proliferation 
(Dey et al., 2008). However, it has been shown that KDM5A promote proliferation in cancer cells. 
This shows that EMSY can regulate proliferation within a cell by binding to KDM5A in cancer cells 
or KDM5B in non-cancer cells. KDM5A is involved in regulating EMT in the ovarian cancer cell 
line SKOV3 (Feng et al., 2017). It was found that when the expression of E-cadherin was decreased 
and the expression of N-cadherin was increased, there was an increase in KDM5A expression. 
Therefore, it is hypothesised in this project that EMSY may interact with KDM5A during EMT in 
lung epithelial cells.     
It has been observed that EMSY is a transcriptional repressor regulated by PI3K/Akt that contributes 
to EMT in lung epithelial cancers. Therefore, EMSY may be a regulator of EMT in lung cancer. An 
aim of this project was to determine whether EMSY is a regulator of EMT, and whether EMSY 
regulates the expression of genes that show a change in expression during EMT.  
2.3. EMT is associated with wound healing in lung epithelial cells   
Epithelial-mesenchymal transition (EMT) describes the change in the phenotype of a healthy 
epithelial cell that usually interacts with the basement membrane into a migratory cell, a process that 
is important to achieve re-epithelialization during wound healing (Yan et al., 2010). EMT was first 
described as being an important cellular program activated during embryogenic development. 
However, later findings found that EMT is also activated during cancer progression to enable 
mesenchymal cells to have enhanced motile capacity and invasiveness properties (Son and Moon, 
2010). It was also found that EMT occurs during wound healing and fibrosis, which has been termed 
partial EMT (Arnoux et al. 2005).  
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Wound healing in lung epithelial cells is a complex process that involves an interplay between 
numerous cellular and molecular processes. After a wound injury the lung epithelium can be repaired 
through stimulation of proliferative and differentiation programs, or undergo inappropriate 
remodeling, that might include excessive apoptosis and epithelial-mesenchymal transition (EMT) 
(Wynn, 2008).  
When the epithelial layer has been damaged, a four-phase wound healing process is initiated (Block 
et al., 2004).The first phase is an inflammatory response, with the release of pro-inflammatory 
cytokines and chemokines such as interleukin-8 (IL-8). This recruits leukocytes to the damaged area 
to from a temporary seal over the wound area (Shaw and Martin, 2009). The second phase of wound 
healing is the proliferation phase where the connective tissue and a temporary extracellular matrix 
(ECM) is rebuilt (Darby et al., 2014). Following the proliferation phase the wound re-
epithelialization stage occurs. During this phase the temporary ECM matures, with disordered 
collagen III being replaced by collagen I which is structurally supported by fibroblasts and MMPs 
(Gardner et al., 2010). Matrix metalloproteinases (MMPs) are a group of enzymes that are responsible 
for the degradation of extracellular matrix proteins during re-epithelialization stage of wound healing 
(Sorsa et al., 2004). The epithelial barrier is also re-established to protect internal cells from external 
pathogens. The epithelial barrier is repaired by the recruitment of new progenitor cells to the damaged 
site through proliferation and migration. This allows the regenerated epithelial cells to obtain their 
normal morphology by reforming and attaching to the basement membrane (Leoni et al., 2015).            
The purpose of EMT during wound healing is to enable epithelial cells to become motile through the 
loss of cell adherent contact and polarity, a process known as migration. During cell migration, cells 
undergo phenotypic differentiation to re-establish the integrity and function of the epithelial barrier 
(Crosby and Waters, 2010), and this involves changes in gene expression within the motile cells. 
When lung epithelial cells become motile during EMT, the adherent complexes between adjacent 
cells undergo changes that include a decrease in E-cadherin gene expression and an increase in N-
cadherin gene expression (Serrano-Gomez et al., 2016). Moreover, recent in vitro wound healing 
assays have shown that E- and N-cadherin, regulate the speed and direction cells migrate during 
wound healing (Harris, 2012). Cell migration is initiated by the development of extended 
lamellipodia, at the front of the migratory cells. Within the nucleus of the cell the mesenchymal 
transcription factor Zeb, binds to the E-box element at the promoter site of the gene encoding E-
cadherin (CDH1), repressing CDH1 gene expression (Lamouille et al., 2014). The down-regulation 
of CDH1 is balanced by the increase in gene expression of the gene encoding N-cadherin (CDH2), 
resulting in a ‘cadherin switch’ that alters cell adhesion junctions and allows the activation of the 
gene Rac1(Lamouille et al., 2014). Rac1 is a gene that allows cadherin adhesions transmembrane 
proteins to cross communicate to integrin junction proteins. Once the Rac1 is activated, α and β-
integrin transmembrane proteins attach to the extracellular matrix (ECM) and form focal complexes 
(Crosby and Waters, 2010). These focal complexes anchor the actin cytoskeleton to the extracellular 
matrix. Once that the actin cytoskeleton is linked to the extracellular matrix, any new actin molecules 
added to the actin cytoskeletal scaffold are added to the leading edges of the lamellipodia and pushes 




 Figure 1.3: Cell migration  
During migration E-cadherin gene expression is down regulated and N-cadherin gene expression is 
up regulated. This results in a ‘cadherin switch’ that alters cell adhesion junctions and allows the 
activation of the gene Rac1.  Rac1 then activates α and β-integrin which anchor the actin cytoskeleton 
to the extracellular matrix. Once that the actin cytoskeleton is linked to the extracellular matrix, any 
new actin molecules added to the actin cytoskeletal scaffold are added to the leading edges of the 
lamellipodia and pushes the plasma membrane forward.    
2.4. Cancer progression and EMT at a transcriptional level  
Various studies have shown that an EMT event occurs during tumor progression and malignant 
transformation to enable cancer cells to take on invasive and metastatic potential (Morel et al., 2012, 
Van Zijl et al., 2009). The EMT event is typically thought to occur during the later stage of malignant 
transformation to promote metastasis. Tumor metastasis a multi-step cell-biological processes in 
which tumor cells detach from their primary site (EMT), and relocate to a distal site on the body to 
form a secondary tumor and re-transform into no-motile lung carcinoma cells, using the process 
mesenchymal‐to‐epithelial transition (MET)  (MacLean et al., 2014). The complexity of EMT and 
metastasis lies in the heterogeneity of the tumor cell population and the transcription factors that 
control transcription of genes regulating the process of EMT. Due to the genetic heterogeneity of the 
cell population, not all cells will undergo EMT instantaneously and not all cancer cells that have 
successfully undergone EMT will metastasize (Heerboth et al., 2015).   
During invasive EMT carcinoma cells lose their cell to cell adhesion junctions and dissociate form 
each other to form single cell migration (Yu and Elble, 2016). Cell migration involves the repression 
of epithelial markers such as E-cadherin and an activation in mesenchymal markers such as N-
cadherin and Vimentin (Xiao and He, 2010). Upregulation of N-cadherin and vimentin stabilizes β-
catenin, activating mesenchymal transcription factors such as Snail, Zeb and Twist. These 
transcription factors bind to the e-box at the promoter region of E-cadherin, leading to the 
transcriptional repression of E-cadherin (Shirkoohi, 2013, Xiao and He, 2010).  
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Following loss of cell-cell adhesion through repression of E-cadherin at the adhesion junctions, cells 
start to dissociate form each other, causing cell morphology to change to prolonged forms due to 
action remodeling between the adhesion junctions (Shirkoohi, 2013). E-cadherin is considered, to 
some extent, to be a tumour suppressor. In various carcinomas E-cadherin is transcriptionally 
silenced and re-expression of E-cadherin to reduces the aggressiveness of tumour cells (Lewis-Tuffin 
et al., 2010). In lung cancer, functional loss of E-cadherin can be due to protein coding mutations or 
dysregulated post-translational modification. It may also be due to hypermethylation at the CpG 
islands at the CDH1 promoter , causing transcriptional silencing of this gene (Kiesslich et al., 2013). 
It has been estimated that 70% of promoters located near the transcription start site of a gene will 
contain a CpG island (Saxonov et al., 2006). When DNA methylation occurs at the cytosine residue 
on the CpG site of a gene it causes stable gene silencing (Bird, 2002). Hypermethylation of the CDH1 
promoter in various cancers including lung cancer  involves the recruitment of histone deacetylases 
and transcriptional repressors to silence CDH1 expression (Hosseini–Varnamkhasti and Turner, 
2013). Following loss of cell to cell adhesion through repression of E-cadherin at the adhesion 
junctions, lead to cells dissociating form each other. This enabled that cells to take on a migratory 
invasive behavior phenotype (Knights et al., 2012). Given that EMSY, the gene product of C11orf30, 
is a transcriptional repressor, one aim of the work described here is to test whether EMSY binds to 
CpG islands at the promotes of epithelial and mesenchymal genes.  
Numerous studies have found that there is a correlation between EMT and the progression of lung 
cancer. Several data sets showed that there was an association downregulated E-cadherin expression 
and upregulated Twist and Snail expression with poor prognosis in lung cancer patients. Though, it 
must be stated that a research paper done by Pruklin et al., demonstrated that although an EMT event 
was observed in small cell lung cancer (NSCLS), due to upregulated gene expression of transcription 
factors such as Snail, Zeb and Twist, particularly in squamous cell carcinoma, there was no down-
regulated expression of E-cadherin or overexpression of N-cadherin associated with poor prognosis 
for patients with NSCLC (Xiao and He, 2010, Prudkin et al., 2009). Understanding how EMSY might 
regulate the gene expression of epithelial and mesenchymal transcription factors during the processes 
of EMT in wound healing and lung cancer progression, could lead to the development of novel 
treatments for lung cancer patients with EMSY amplified tumours.                   
2.5. Project Aims 
Due to the apparent dual roles of EMSY as a transcription activator and repressor, and the uncertainty 
of the role of EMSY in epithelial barrier integrity and metastasis, research into the expression and 
function of EMSY in the context of lung epithelial EMT was the focus of this research project. This 
project sought to establish whether EMSY was a direct regulator of TGF-β-dependent gene 
expression in the context of wound healing and epithelial–mesenchymal transition (EMT). The 
research question was extended to investigate whether EMSY also regulates key factors involved in 
wound healing such as E-cadherin and N-cadherin.   
Based on the observation that EMSY is a transcriptional repressor, and that the cellular localisation 
of EMSY is regulated by Akt/PI3K, a hypothesis tested in this study is that EMSY, the gene product 
of C11orf30, regulates the transcription genes encoding the cadherin adhesion transmembrane 
proteins during lung epithelial barrier during wound healing. 
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The aims of this project were:   
1. To investigate the expression, function and location of EMSY in the non-cancerous 
human bronchial epithelial cell line BEAS-2B, and to compare this to EMSY 
expression in cancerous bronchial epithelial cell line, A549.  
2. Use ChIP assays to test if EMSY is a direct transcriptional regulator of E-cadherin 
and N-cadherin, both of which are involved in the early stage of epithelial–
mesenchymal transition (EMT).  
3. Test whether the C11orf30/LRRC32 intergenic genetic locus is a TGF-β responsive 
enhancer and whether this enhancer regulates expression of C11orf30.  
 
2.6. Overview of project findings:  
Immunohistochemistry staining has shown that EMSY becomes nuclear during the migration EMT 
stage of wound healing in BEAS2B cells. The immunohistochemistry staining and chromatin-
immunoprecipitation analyses revealed that the demethylase KDM5A gene, co-localizes and binds to 
nuclear EMSY during wound healing EMT. However, western blot and immunohistochemistry 
staining data showed that, during TGF-β1 induced EMT C11orf30 expression, is down-regulated and 
relocates into the cytoplasm. Chromatin-immunoprecipitation analyses also indicated that EMSY 


















3.1. Cell culture 
For this project two different cell lines were used: BEAS2B and A549 cells.  
The BEAS2B cell line is a normal healthy bronchial epithelial cell line derived from non-cancerous 
individuals which was infected with a AD12-SV40 virus and cloned to create an immortalized 
phenotype (Garcia-Canton et al., 2013, Stewart et al., 2012).  
The A549 cell line is a adenocarcinomic human alveolar basal epithelial cell line that is derived from 
a cancerous lung tumor tissue form a 58 year old Caucasian male (Soto-Pantoja et al., 2009). 
The main genetic differences between these cell lines is that the A549 cells have 2 main mutations 
present. It has a KRAS gene codon 12-point mutation and Smarca4 mutations (Okudela et al., 2004). 
Specific cancer-associated mutations occur during tumorigenesis, that drive tumor progression in 
various cancers. The heterogeneity of tumors due to having various mutations, has implications for 
cancer treatment options for patients (Loeb et al., 2003).        
 
A549 an cancerous lung human epithelial tissue, from lungs (ATCC® CCL-185™) and BEAS-2B 
cells an lung human epithelial tissue, from bronchus (ATCC® CRL-9609™) were grown in a cell 
culture medium, consisting of Dulbecco’s Modified Eagle Medium (DMEM) and 10 % fetal bovine 
serum (FBS) at 37 °C, in a humidified atmosphere containing 5 % CO2. 
 
3.2. Matrigel Coated plates 
All plates used were coated with a 1/50 dilution of matrigel (100µl of matrigel diluted in 5ml DMEM 
free media) and incubated at 37°C for 30 minutes. After 30 minutes, the matrigel solution was 
removed and cells were seeded.  
Plate Size Volume of diluted matrigel mixture added 
to each well 
8-well chamber slide 250µl 
6-well plates 1.5mL 
12-well plates 1mL 











3.3. Scratch Assay  
Confluent monolayers of A549 or BEAS-2B cells were grown in 10% FCS overnight in an 8-chamber 
well slides or 10 cm plates or 12 well plates or 6 well plates, for confluent monolayers to form. The 
next day the cells were starved with 1% FCS and cells were scratch and treated with TGF-β1 
overnight. The following day the cells were scratched for various periods (2, 6, or 12 hours) with a 
200ul pipette tip or plastic comb, generating various scratch gaps. After extensive washing with PBS, 
the cells were placed into 1% DMEM and the cells were once again treated with 1ng/ml TGF-β1. 
Cells were harvested when scratch period ended.   
Plate Size Number of cells seeded. 
8-well chamber slide 1x105 
6-well plates 3x105 
12-well plates 1.5x105 
10cm plates 4x106 
 
3.4. Immunofluorescent 
Cells were seeded at 1x105 on 8-chamber well slides and treated as stated below in Table 2.1. 24 
hours after plating, cells were harvested and fixed in 4% formaldehyde solution for 10 minutes at 
room temperature. After 10 minutes, the cells were washed 3 times for 5 minutes in 0.01% triton 
X100/ Phosphate-Buffered Saline (PBS), after which the cells were blocked in Image-iTTM FX Signal 
Enhancer (Molecular Probes, Oregon, USA) for 30 minutes. Cells were then washed 3 times for 5 
minutes in 0.01% triton X100/PBS. After the final wash, the cells were incubated with primary 
antibodies (EMSY: sc-515469, Santa Cruz Biotechnology, KDM5A: ab70892, Abcam) in blocking 
buffer (1% BSA, 0.01% Triton 100X, 5% FCS in PBS) overnight at 4 °C. Cells were then washed 3 
times for 5 minutes in 0.01% triton X100/PBS. Cells were then incubated with a 1 in 1000 dilution 
of secondary antibodies (Alexa Flour® 555 goat anti-mouse IgG and/or Alexa Flour® 488 goat anti-
rabbit IgG) in blocking buffer for 1 hour in the dark. Cells were washed 2 times for 5 minutes in 
0.01% triton X100/PBS and the nucleus was stained using 1 µg/ml of Hoechst 33342 (Molecular 
Probes, Life Technologies™, Austin) in blocking buffer for 10 minutes at room temperature in the 
dark. Cells were then washed a final time in 0.01% triton X100/PBS for 5 minutes.  2-3 drops of 
ProLong® Gold antifade reagent was placed on the slide and covered with a glass cover slip. The 
slides were analyzed and viewed on an Olympus BX43 Microscope, installed with an X-Cite series 
120Q EXFO Halogen Lamp, and cell Scence standard software.   
 
Table 2.1: Treatment of cells for immunofluorescent imaging  
Treatments used for immunofluorescences staining on BEAS-2B and A549 cells.        
Stimulus/Treatment   Concentration Time 
FCS 1% 24 Hours 
2 Hour Scratch  - 2 Hours 
TGF-β1 1ng/ml 24 Hours 





3.5. cDNA synthesis and Quantitative Real-Time PCR  
RNA was extracted using the PureLink® RNA Mini kit (Ambion®/Life TechnologiesTM, Austin, 
TX, USA). cDNA was synthesized from 1 μg of RNA, using the SensiFAST cDNA Synthesis Kit, 
following the manufacturer’s directions. Quantitative real-time PCR was carried-out using 2x 
SensiFASTTM SYBR Lo-ROX Kit (Bioline, London, UK), 1 µl of 0.2 µM of forward and reverse 
primers was added to 1µL cDNA from a 20 µl reaction, diluted 1:5 and 5µL 2x SYBR green. Water 
was added to achieve a final volume of 10 μl. Reactions were transferred to an ABI 7500 FAST real-
time PCR machine using a 10 minute, hold at 95°C, followed by 45 cycles of 5 s at 95°C, 5 s at 53°C 
and 20 s at 72°C. Threshold cycle (Ct) values were determined and SDHA was used as a reference 
gene to normalize RT-qPCR data. Primer sequences are shown in Table 2.2.    
Table 2.2: Syber-Green Primer constructs:   
Primer sequences used for Quantitative Real-Time PCR.  
Targets  Primer Sequence  
CDH1_FWD1 sybr cctgagctccctgacaaaaa 
CDH1_REV1 sybr ccaccagggtatacgtaggg 
CDH2_FWD1 sybr ggaccgagaatcaccaaatg 
CDH2_REV1 sybr agatctgcagcgttcctgtt 
C11orf30_REV1 sybr gggtcgtggacttgacatt 
C11orf30_FWD1 syber tagcagcaccacaacaagag 
SDHA_REV1 syber ccaccactgcatcaaattcatg 












3.6. Luciferase report assay to test for enhancer in vitro activity  
Previous s research under taken by Kate Giles, identified a 2.8Kb region between the genes C11orf30 
and LRRC32 that might contain a possible enhancer that regulates the expression of C11orf30. 
Section 2.5 will discuss the experimental process that was followed to test this region for enhancer 





Figure 2.1: In silico data illustrate in a region between C11orf30 and LRRC32 that may be a possible 
enhancer. The locus is located in a region marked with epigenetic markers such as H3k4me3 and 
H3k4me1. High methyl levels of H3k4me3 and H3k4me1indicated active enhancers.   
In vitro Luciferase Assays 
A549 or Beas-2B cells were seeded at 1.5x105 cells per well in a 12 well plate (3524, costar, 
Corning Incorporated). Cells were transfected 24 hours later by using 1000ng of Luciferase plasmid, 
20ng β-galactosidase plasmid and 2µl P3000 reagent (supplier) diluted to a final volume of 50µl 
with Opti-MEM reduced serum media (31985, Gibco). In a separate tube, 1.5µl of Lipofectamine 




constructed by Kate 
to test for enhancer 
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Opti-MEM reduced serum media (31985, Gibco). Diluted DNA and Lipofectamine 3000 was 
then combined and incubated at room temperature for 10 minutes and then added to the cells. The 
plate was incubated for 24 hours at 37°C, 5% CO2. On the next day the transfection medium was 
removed and transfected cells were treated as indicated (Table 2.3).     
  
Table 2.3. Cell culture conditions used for luciferase assays of A549 and BEAS-2B cells 
Treatment Concentration Time 
 FCS (control) 1% 24 hours 
1% FCS + TGF-β1  1ng/mL 24 hours 
1% FCS + 2 hour scratch  24 hours  
1% FCS + TGF-β1+ 2 hour 
scratch 
1ng/mL 24 hours  
1% FCS + 24 hour scratch  24 hours  
1% FCS + TGF-β1+ 24 hour 
scratch 
1ng/mL 24 hours  
 
Transfected A549 and BEAS-2B cells were harvested by washing cells once in PBS and lysed by 
adding 100µl of 10x cell culture lysis reagent that was diluted to 1x concentration (E1531, Promega) 
with MilliQ® water, and incubated on ice for 5 minutes. Lysates were collected and centrifuged at 
16,000 x g at 4oC for 5 minutes to remove cellular debris. Luciferase activity was measured using a 
luminescence assay (kit) (E1500, Promega). The luciferase reagent was prepared by adding the 
luciferase assay substrate with the luciferase assay buffer. The Beta-GLO normalization reagent 
(E4720, Promega) was pre-prepared by the seller company and only had to be divided into 1ml 
aliquots and stored at -20oC. Luciferase activity for each cell lysate was measured using the 
FluoSTAR optima plate reader (Top down optic, 5 second exposure, emission on lens). For each 
assay 20µl of cell lysate was added to 100µl of luciferase reagent and luminescence was measured. 
To normalize that data 25µl of Beta-GLO reagent was added to 25µl of cell lysate and left in the dark 
at room temperature for 30 minutes, after which luminescence for each sample was measured. 
Relative light units (RLU) expressed as a percentage of the enhancer pGL3-PV activity was 
calculated as follows: 
(1) Luciferase activity ÷ Beta-GLO activity/0.02 = Normalised Activity (NA) 
(2) NA[Enhancer Reporter Plasmid] ÷ NA[pGL3-PV] = Relative Light Units (RLU) 
 
3.7. PI3K/Akt (LY294002) Inhibition assay 
A549 and BEAS-2B cells were seeded at 50,000 cells per well in an 8 chamber well slide. The 
following day the media was replaced with reduced serum growth medium (DMEM media with 
Antibiotic-Antimycotic and 1% FCS) in the presence of 20µM LY294002 or DMSO for 1 hr. After 
1 hour the cells were treated occurring to Table 2.4. Once all treatments were completed, the cells 
were immunofluorescent (see section 2.3).  
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Table 2.4: PI3K/Akt inhibition assay treatments.  
Stimulus/Treatment Concentration Time 
DMSO  24 Hours 
2 Hour Scratch  - 2 Hours 
TGF-β1 1ng/ml 24 Hours 
2 Hour Scratch + TGF-β1 1ng/ml 2 Hour/24 Hour 
 
3.8. Western Blot  
Cells were seeded at 4x106 on 10cm plates and treated as presented in Table 2.1. Cells were washed 
once in PBS and harvested with a cell scraper and centrifuged at 200g at 4°C for 5 minutes. The 
supernatant was removed and 150µl of buffer A (1% NP-40, HEPES pH7.5 10mM, KCl 10mM, DTT 
0.5mM with protease inhibitor) was added to cell pellet and incubated on ice for 15 minutes. Cell 
lysate was drawn through a fine-gauge needle 5 times and then centrifuged at maximum speed at 4°C 
for 2 minutes. Supernatant was collected and marked as cytoplasmic extract. The nuclear pellet was 
resuspended in 50µl of buffer C (HEPES 20mM, Glycerol 20%, KCl 500mM, MgCl2 1.5mM with 
protease inhibitor) and incubated on ice for 30 minutes, with vortexing for 10 seconds, every 10 
minutes. After 30 minutes, the nuclei were centrifuged at maximum speed at 4°C for 10 minutes and 
supernatant was collected and marked as nuclear extract. Protein concentrations were determined 
using a nanodrop spectrophotometer (NanoDrop™ 2000/2000c) and 30µg protein of each sample 
(nuclear and cytoplasmic) was separated by SDS polyacrylamide gel electrophoresis (PAGE) in a 
Mini-PROTEAN® TGX™ Precast Gel. The proteins were transferred onto a nitrocellulose 
membrane, using the Bio-Rad Turbo Blotter at a constant current of 1.0 A and 25V for 30 minutes. 
The membrane was blocked for 30 minutes in blocking buffer (5% skim milk with 0.1% Tween-20). 
The membrane was then incubated with the primary antibodies overnight at 4°C (EMSY: sc-515469, 
Santa Cruz Biotechnology, Claudin: #4933, Cellsignal). The following day the primary antibody was 
washed off by adding a sufficient amount of wash solution (1 x TBS, 1mL 0.1% Tween-20) to cover 
the membrane and incubating for 30 minutes at room temperature with gentle shaking. The washing 
step was repeated 3 more times. After the final wash step, the membrane was incubated with 
secondary antibody at a dilution of 1/5000 (Horse radish peroxidase conjugated antibody), in 
blocking buffer at room temperature, with gentle shaking for 1 hour. Once incubation period was 
completed the membrane was washed a further 4 times in washing buffer, for 30 minute intervals 
with gentle shaking. Chemiluminescent detection was carried out as per manufacturer’s instructions 
and membrane was imaged using the Odyssey® CLx Infrared Imaging System (LI-COR 
Biosciences).                     
3.9. Invasion Assay   
25µl of matrigel was added to 1.25ml DMEM free media. 100µl of this mixture was added into the 
inserts of a 12 well transient plate and left overnight to harden, at 37°C. The following day A549 and 
BEAS-2B cells were trypsinized and resuspended in DMEM with no added Antibiotic-Antimycotic 
or FCS (Basal DMEM media). Cells were seeded at 1x105 onto each matrigel hardened insert and 
the final volume in the inserts was brought up to 500l with basal DMEM media. To the bottom of 
each chamber was added 1.5 ml of growth medium (DMEM media with Antibiotic-Antimycotic and 
10% FCS). Cells were either treated with 1ng/ml TGF-β1 or left untreated, and incubated overnight 
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at 37°C, 5% CO2. After 24 hours, the media was removed from the inserts, and the cells were washed 
twice with PBS. The cells were fixed using 4% formaldehyde solution for 2 minutes at room 
temperature. After 2 minutes, the formaldehyde was removed and cells were washed twice in PBS. 
Cells were then permeabilized in 0.01% triton X100/ Phosphate-Buffered Saline (PBS) for 20 
minutes at room temperature. Once cells were permeabilized, they were washed twice with PBS and 
the non-invasive cells in the upper chamber were removed using a soft cotton bud. The cells were 
then stained using 250µl of 0.01% Crystal Violet diluted in 0.02% ethanol for 10 minutes. The Crystal 
Violet stain solution was removed and cells were washed twice with PBS. Invasive cells were 
visualized and count under a light microscope and live images were taken using a Leica MC170 HD 
camera.  
3.10. Primer design (CpG regions) 
Using the UCSC Genome Browser, CpG islands were identified near the transcription start sites of 
genes involved in epithelial mesenchymal transition. The CpG sequences were downloaded and the 
Primer3 online program was used to generate primer pairs for the DNA sequence of interest. Primer 
pairs were checked using In Silico PCR in the UCSC browser (UCSC Genome Browser and Primer3 
Input (version 0.4.0).  
Table 2.5: Primer sequences for analyzing CpG islands  
Targets  Primer Sequence  
CDH1_FWD CTGAATTCCACAACGGCTTT 
CDH1_REV  GCATCAATCTAGGGCCACAT 
Zeb_ FWD GCACAGGGTACAGGGAGAAT 
Zeb _REV TGTCGGAGTTGGAAAGGTAAA 
FOXA2_ FWD CGACCCGAGTCCTCATTTAC 
FOXA2 _REV TTTTCGGAGAGACTGGGAGA 
CDH2_ FWD ATGGAGAGCGAGCTGATGAC 
CDH2_ REV TCCCCAGCTCCTTGATCTCT 
 
3.11. Flow cytometry 
Cells were seeded at 4.5x106 cells per well on a 6 well plate and treated as shown on Table 2.6. The 
cells were scraped off using a cell scraper and centrifuged at 300g for 5 minutes. Cells were 
resuspended in 500µl of ice cold PBS and added to a cell shredder (352235, Falcom) and the cells 
were centrifuged at 300g for 3 minutes. A cell count was performed and cells were divided into 2 x 
1.5ml centrifuge tubes for either whole cell flow staining or nuclear flow staining.  
Whole cell flow staining:  
The cells were centrifuged at 450g for 4 minutes and supernatant was removed. The cells were 
resuspended with 50 µl stain flow buffer (10% FCS/PBS) and gently pipetted up and down. Each 
cell sample was fixed by adding 125µl of fixation/permeabilization (BD 554715, BD 
Cytfix/Cytoperm TM PLUS) for 20 minutes at 4°C. Cells were then centrifuged at 450 x g for 5 
minutes, and the supernatant was removed. Cells were washed twice with 500µl of 1X BD perm/wash 
buffer (BD 554715, BD Cytfix/Cytoperm TM PLUS), and centrifuged at 450 x g for 5 minutes at 4°C. 
Cells were then resuspended in 50µl of BD Perm/Wash ™ buffer containing 5µl of EMSY antibody 
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(EMSY: sc-515469, Santa Cruz Biotechnology), and incubated at 4°C for 30 minutes, in the dark. 
Cells were pelleted at 450g for 5 minutes and supernatant was removed. Cells were washed twice in 
500l 1x Wash/Perm ™ buffer and centrifuged at 450g for 5 minutes. Cells were then resuspended 
in 50µl of BD Perm/Wash ™ buffer, containing 1µl of secondary antibody (Alexafluor-488 anti-
mouse-body), and left in the dark for 30 minutes at 4°C. After the incubation period the cells were 
pelleted at 450g for 5 minutes, and supernatant was removed. Cells were washed twice in 500 µl of 
1x Wash/Perm ™ buffer and supernatant was removed. Cells were resuspended in 100µl of staining 
buffer and flow cytometric analysis was performed using the BD Accuri™ C6 Plus Flow Cytometer.  
Nuclei cell Flow Staining:              
The cells were resuspended in 50ul Buffer A (1% NP-40, HEPES pH7.5 10mM, KCl 10mM, DTT 
0.5mM with protease inhibitor) was added to cell pellet and incubated on ice for 15 minutes. Cell 
lysate was drawn through a fine-gauge needle, 5 times, and centrifuged at max speed at 4°C for 2 
minutes. Staining for flow cytometry was done in the same way as described for whole cell analysis. 
Table 2.6: Cell culture conditions used for flow cytometry of BEAS-2B cells  
Treatment Concentration Time 
FCS (control) 1% 24 hours 
1% FCS + TGF-β1 1ng/mL 24 hours 
1% FCS + 2 hour scratch  24 hours 
1% FCS + TGF-β1+ 2 hour 
scratch 
1ng/mL 24 hours 
 
3.12. Chromatin-Immunoprecipitation 
ChIP Assay Preparation 
BEAS-2B cells were seeded at 4x106 on 10cm matrigel coated plates and treated as seen on Table 
2.6. The cells were harvested by treatment with trypsin and and then centrifuged for 5 minutes at 
180xg. The supernatant was discarded, cells were re-suspended in 1mL PBS (phosphate buffered 
saline) and centrifuged for 5 minutes at 180xg. The supernatant was again discarded and the cells 
were cross-linked by adding 10mL of 1% formaldehyde to the cell pellet for 10 minutes at room 
temperature. To quench the cross-linking reaction, 1.1mL of 1.25M glycine was added to the cell 
pellet. The cells were then centrifuged at 180xg for 5 minutes at 4°C and the supernatant was 
discarded. The cells were washed by gently re-suspending in 10ml of ice-cold PBS and centrifuged 
for 5 minutes at 180xg. The supernatant was discarded and the cell pellet was re-suspended in 200L 
per 1x106 cells of 1X working lysis buffer. The cell suspension was transferred into 1.5ml centrifuge 
tube and incubated on ice for 10 minutes. The cell suspension was then vortexed for 10 seconds and 
centrifuged for 5 minutes at 2350xg. The supernatant was removed and the cell pellet was 
resuspended in 50L of working extraction buffer per 1x106 cells, to a maximum of 500L. To 
release cross-linked chromatin and nuclei, the cell suspension was incubated on ice for 10 minutes 
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and vortexed every 2 minutes. The chromatin was sheared using a Branson Digital Sonifier with a 
3mm tip, at 25% amplitude for 30 seconds ON and 30 seconds OFF for 10 cycles. After sonication, 
the samples were centrifuged for 5 minutes at 14,000xg and 40C and the supernatant containing the 
sheared chromatin was transferred to a new 1.5ml centrifuge tube. To verify the size of sheared 
chromatin, 20L of sonicated chromatin was removed from each sample, and electrophoresis was 
carried out to verify chromatin fragment length. For the INPUT sample, 45L of the sonicated 
chromatin sample was aliquoted into a new 1.5mL centrifuge tube and stored at -20°C for later use. 
To the remaining 135L of sheared chromatin 1.1ml of IP buffer (EDTA pH8 1.2mM; SDS 0.01%; 
Triton-X-100 1%; Tris-HCl pH8.1 16.7mM; NaCl 167mM; Protease Inhibitor) was added and 
samples were vortexed for 5 seconds. Samples were stored at -20°C overnight and 
immunoprecipitation was carried out the following day.  
Verification of chromatin fragment length (200-500bp): 
1L of proteinase K was added to the 20L of sonicated chromatin that was removed from each 
sample. Samples were vortexed for 5 seconds, and incubated for 30 minutes at 55°C. The sonicated 
chromatin was then incubated at 98°C for 10 minutes and centrifuged for 1 minute at 14,000xg. The 
supernatant was transferred to a new 1.5mL eppendorf tube, and the sample was purified according 
to manufacturer’s instructions using the Bioline Isolate II PCR and Gel Kit (Cat No. BIO-52059). 
10L of the purified chromatin was loaded on a 1.5% agarose gel and electrophoresis was carried 
out to visualize DNA fragment size.  
 




The chromatin samples that had been diluted in IP buffer were split equally into 4 x 1.5mL eppendorf 
tubes such that the final cell concentration is equivalent to approximately 1x106 cells per tube. One 
eppendorf tube served as a positive control (H3K4me3); another eppendorf tube served as a negative 
control (beads only) and the last 2 tubes was used for the antibodies of interest (EMSY, KDM5A, 
H3k4me1). Between 2g of antibodies (EMSY: sc-515469, Santa Cruz Biotechnology, KDM5A: 
ab70892, Abcam, H3k4me3: ab8895, Abcam,) were added to the appropriate samples, and left to 
incubate overnight, at 4°C with rotation. 
The following day, 80µl of magnetic bead mix (Magna ChIP Protein A+G Magnetic Beads, 16-663, 
MERCK) and 1 mL of IP buffer, are combined and mixed once by inversion. The beads mix was 
placed into a magnetic bead rack (DynaMagth Magnetic particle concentrator, 12321D, Invitrogen) 
and supernatant was removed. The beads were washed twice more with 1mL of IP buffer. The beads 
were resuspended to a final volume of 6 ml with IP buffer (300L per immunoprecipitation: each 
1.5ml eppendorf tube equaled an immunoprecipitation reaction). 300L of the bead/IPbuffer mix 
was aliquoted into the appropriate number of 1.5ml tubes. The antibody/chromatin samples were 
pelleted by centrifuging at 14,000xg for 10 minutes at 4°C to remove insoluble material. After 
centrifuging cells, 250L of the antibody/chromatin supernatant, were removed and transferred to 
each 1.5 eppendorf tube containing the beads/IP buffer. Samples were rotated at 4°C for 1 hour. Once 
the incubation was completed, the samples were placed in the magnetic bead rack (DynaMagth 
Magnetic particle concentrator, 12321D, Invitrogen) and supernatant was removed. Samples were 
removed from rack and cells were resuspended and washed twice with 1 ml low salt buffer (EDTA 
pH8 2mM; 0.1% SDS; Triton-X-100 1%; Tris-HCl pH8.1 20mM; NaCl 150mM), washed once with 
1 ml high salt buffer (EDTA pH8 2mM; 0.1% SDS; Triton-X-100 1%; Tris-HCl pH8.1 20mM; NaCl 
500mM), and then washed a final time with 1 ml TE (Tris-Cl pH7.5 10mM; EDTA pH8 1mM) buffer. 
After the final wash, cross-linked chromatin was eluted from the magnetic beads by adding 100L 
of elution buffer (1% SDS, NaCl 50mM, Tris (pH 7.5) 50mM, EDTA 5mM) to chromatin/bead 
mixture and incubating at 30°C, for 15 minutes, with vortexing every 5 minutes. The eluted cross-
linked, chromatin was centrifuged for 1 minute at 2000xg and the supernatant transferred into new 
1.5mL eppendorf tubes. A second elution was performed. To the INPUT samples and to the eluted 
cross-linked, chromatin, 8L of 5M NaCl and 2L of RNase A (10mg/mL), were added and samples 
were incubated at 65°C overnight, with shaking. The following day the, 2L of proteinase K 
(20mg/mL) was added to each sample, and the samples were incubated for 1hr at 60°C with shaking. 
The reverse cross-linked DNA was then purified, using the Bioline Isolate II PCR and Gel kit 
according to manufacturer’s instructions.   
QPCR Chip analyses:     
Quantitative real-time PCR was carried-out using SensiFASTTM SYBR Lo-ROX Kit (Bioline, NSW, 
AUS), 1 μL 1 µl of 0.4µM of forward and reverse primers was added to 2µL Chip sample and 10µL 
SYBR green. Water was added to achieve a final volume of 20 μl. Reactions were transferred to an 
ABI 7500 FAST real-time PCR machine using a 10-minute, soak at 95°C, followed by 45 cycles of 
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5 s at 95°C, 5 s at 53°C and 20 s at 72°C. Threshold cycle (Ct) values were determined and SDHA 
was used as a reference gene to normalize RT-qPCR data. Primer sequences are shown in Table 2.5. 
Normalized data calculations:        
The Ct value of each IP was normalized to the input for any difference in chromatin sample 
preparation.  
ΔCt (normalized ChIP) = (Ct (IP) – (Ct(input) – Log2 (input dilution factor))) 
Where input dilution factor = fraction of input chromatin saved.  
Next the difference between the normalized experimental control sample (ES) and the control sample 
(CS) was determined  





4.1. Plastic VS Matrigel coated plates 
All commercial cell culture plates are made of plastic. A draw-back when using plastic plates is that 
cells have difficulty attaching to the plastic surface, due to it being hydrophobic.  In the absence of 
contact with a basement membrane, key adhesion-dependent signals may be missing or dysregulated, 
leading to aberrant changes in gene transcription of genes involved in the adhesion junctions. 
Adherents junctions keep cells attached to each other and to the tissue culture plate surface (basement 
membrane). The disadvantage of using plastic plates can be overcome by using cell culture plates 
that have been coated with an ECM extract called Matrigel (Hughes et al., 2010). Matrigel serves as 
an extracellular matrix component on the plate surfaces to ensure that cells attach and remain in an 
undifferentiated state. It also provides ligands for cell adhesion receptors such as integrins. This 
provides important migratory, survival and differentiation signals to the cells. (Hughes et al., 2010). 
Initially, the expression of genes encoding two main adherens junction proteins, E-cadherin and N-
cadherin, were tested in the non-cancerous BEAS-2B lung epithelial cell line when cultured on a 
plastic or matrigel substrate under different conditions known to induce migration and/or EMT. The 
BEAS-2B cell line is a lung epithelial cell line derived from a non-cancerous individual that was 
infected with a AD12-SV40 virus and cloned to create an immortalized phenotype (Garcia-Canton 
et al., 2013, Stewart et al., 2012). During early EMT the gene expression of CDH2 (N-cadherin) 
increases, whereas the gene expression of the epithelial- specific gene CDH1 (E-cadherin) decreases 
(Campbell and Casanova, 2016). Seeding BEAS-2B cells directly on plastic culture plates, the gene 
expression of CDH1 increased 3.6-fold and the gene expression of CDH2 increased 3.07-fold in 
response to TGF-β1 induced EMT (Fig. 3.1. 1 ± 4.9 Vs 3.6 ± 5.6 and 1 ± 1.8 Vs 3.07 ± 2.8 n=3, 
respectively). The most noteworthy result showed that following a 24 hour scratch, CDH1 gene 
expression increased 8.1-fold whereas, CDH2 gene expression did not change when cells were 
scratched (Fig. 3.1. 1 ± 11 Vs 8.1 ± 12 n=3). Research have shown that when a cell started to migrate 
the gene expression of CDH1 declines. When cells were scratched and treated the gene expression of 
both CDH1 increased 5.7-fold, whereas the gene expression of CDH2 increased 0.6-fold (Fig. 3.1. 1 





Figure 3.1: RNA gene expression of CDH1 and CDH2 during early induced EMT conditions of cells 
seeded on plastic. Experiment was replicated n=3.  
 
In contrast to results obtained from cells plated directly onto plastic, when BEAS-2B cells were 
seeded on matrigel coated cell culture plates, the gene expression of CDH2 increased 3.2-fold during 
TGF-β1 treatment (Fig 3.2. 1 ± 1 Vs 3.2 ± 1.1 n=3). Although CDH1 gene expression decreased 0.4-
fold during TGF- β1-induced EMT (Fig 3.2. 1 ± 0.2 Vs 0.4 ± 0.2 n=3). This is expected as CDH1 is 
down-regulated during EMT (Larue and Bellacosa, 2005). When a 24 hour scratch was generated in 
the BEAS-2B cells, there was an 1.8-fold increase in CDH2 expression (Fig 3.2. 1 ± 1.2 Vs 1.8 ± 2.2 
n=3) There was a 1-fold increase in CDH1 gene expression (Fig 3.2. 1 ± 11.1 Vs 1.0 ± 12.1 n=3) 
when cells were scratched for 24 hours. When cells were scratched and treated the gene expression 
CDH1 increased 4-fold, whereas the gene expression of CDH2 increased 8.3-fold (Fig. 3.2, 1 ± 3.2 
Vs 4 ± 4.2 and Fig. 3.2. 1 ± 0.1 Vs 8.3 ± 1.1 n=3) Overall the gene expression of CDH2 showed a 
greater increase when compared to CDH1, during TGF-β1 induced EMT. Studies done on breast 
cancer has shown that loss of CDH1 is not a necessity for epithelial to mesenchymal transition in 
human breast cancer (Hollestelle et al., 2013). Another paper found that elevated CDH2 expression 







































Figure 3.2: RNA gene expression of CDH1 and CDH2 during early induced EMT conditions of cells 
seeded on Matrigel. Experiment was replicated n=3.  
 
The RNA gene expression data in the A549 cell line showed that when the A549 cells were treated 
with TGF-β1 the gene expression of CDH2 increased 20.2-fold (Fig 3.3. 1 ± 0.6 Vs 20.2 ± 1.6). 
However, the gene expression of CDH1 increased 3-fold (Fig 3.3. 1 ± 1.1 Vs 3 ± 2.1). When the cells 
were scratched for 24 hours the gene expression of CDH2 increased 1.7-fold but when the cells were 
scratched for 24 hours there was a 1-fold increase in CDH1 gene expression (Fig 3.3. 1 ± 0.1 Vs 1.7 
± 1.1 and Fig 3.3. 1 ± 0.1 Vs 1 ± 1.1). The gene expression of CDH1 decreased 1.7-fold when cells 
were scratched for 24 hours and treated with TGF-β1 (Fig 3.3. 1 ± 0.07 Vs 1.07 ± 0.3). When cells 
were treated with TGF-β1 and scratched the gene expression of CDH2 increased 13.7-fold (Fig 3.3 
1 ± 1 Vs 13.7 ± 2). Overall that data has shown that during TGF-β1 treatments the gene expression 
of CDH2 increased and there was slight increase in the gene expression of CDH1. Therefor it shows 






































Figure 3.3: RNA gene expression of CDH1 and CDH2 during early induced EMT conditions of 
A549 cells seeded on Matrigel. Experiment was replicated n=2.  
 
By treating the cells with different stimuli to induce EMT, the gene expression of Zeb did not change 
(Fig 3.4). Although the gene expression of Snail did increase 3-fold when cells were treated with 
TGFβ1 (Fig. 3.4 1 ± 1.1 Vs 3. ± 2.1). This is not a significant value, due to the high standard error. 
This means neither Zeb nor Snail gene expression changed during the EMT conditions chosen. 
However, the gene expression of CDH2 increased and the gene expression of CDH1 decreased, 
during TGF-β1 induced EMT (Fig 3.2). There has been discrepancy between scientist about what 
genes need to be active or repress to stated EMT has occurred. Some sated that to have complete 
EMT occurring transcription facts such as Snail and Zeb need to be active, as these are the 
transcription facts that drive the EMT process. They stated that if the gene expression of CDH1 and 
CDH2 changes but not Snail or Zeb, only partial EMT is occurring. Though others have stated that 
loss of CDH1 and CDH2 is not needed for the cells to undergo EMT. (Lamouille et al., 2014, Wang 












































Figure 3.4: RNA gene expression of Snail and Zeb during early induced EMT conditions of cells 
seeded on matrigel. Experiment was replicated n=3.   
 
4.2. Treating cell with TGF-β1 for 24 hours induces invasion in both BEAS-2B and A549 
cells 
To correlate changes in gene expression with phenotypic changes typically associated with EMT, 
the invasiveness of BEAS-2B and A549 cells in response to TGF-β1 was tested. The BEAS-2B cell 
were starved with 1% FCS for 24 hours which severed as a control. The average number of invading 
cells were 70. Relative to control BEAS-2B cells cultured in 1% FCS serum media, addition of TGF-
β1 increased the number of invasive cells approximately 4-fold (Fig 3.6. 70 ± 6 Vs 3.06 ± 7.6 and 
Fig 3.5. A-B).  In contrast, when A549 cells were starved with 1% FCS for 24 hours which severed 
as a control the average number of A549 cells invading were 103. Relative to control BEAS-2B cells 
cultured in 1% FCS serum media, addition of TGF-β1 increased the number of invasive cells 
approximately 6.4-fold (Fig 3.6. 103 ± 8 Vs 7.10 ± 11.1 and Fig 3.5. C-D). Overall the result 
indicated that when the BEAS-2B and A549 cells were treated with TGF-β1 to induce an early EMT 
event, it was a success as the cells stated became invasive. This mean that by treating BEAS-2B and 
A549 cells with TGF-β1, for 24 hours it served as a suitable EMT stimulator.  
BEAS-2B Cell Line A549 Cell Line 
A)24hr starvation B)TGF-β1 C)24hr starvation D)TGF-β1 
Figure 3.5: Invasion images of BEAS-2B and A549 cells during no treatment and TGF-

































Figure 3.6: 3 Fields were counted and the mean ± SD calculated. Shown is the average the 
total number of invasive cells.  
 
4.3. RNA expression of C11orf30 in BEAS-2B and A549 cell lines during early EMT 
conditions 
The transcriptional repression of CDH1 and upregulation of CDH2 enables cells to acquire 
migratory and invasive behaviour, a hallmark of early EMT (Yang and Yang, 2017). Previous 
literature has shown that C11orf30 is amplified in breast and ovarian cancer. However, the 
expression of C11orf30 in non-cancerous BEAS-2B and cancerous A549 lung epithelial cells is 
not known. Relative to control, the gene expression of C11orf30 increased 1.7-fold in both cell 
lines when cells were treated with TGF-β1 for 24 hours (Fig.3.7. BEAS-2B: 24hr TGF-β1, 1 ± 
0.7 Vs 1.7 ± 1.7, and A549 24hr TGF-β1, 1 ± 0.7 Vs 1.7 ± 1.2 n=3). Scratching monolayer 
cultures of BEAS-2B cells for 24 hours caused a 1.1-fold increase in C11orf30 gene expression 
relative to control (Fig 3.7. 1 ± 0.7 Vs 1.1 ± 1.7). When a 2 hour scratch was generated in BEAS-
2B cells there was a 0.7-fold increase in C11orf30 RNA gene expression (Fig. 3.7. 1 ± 0.4 Vs 
0.7± 1.4, n=3). There was a 0.8-fold increase in the gene expression of C11orf30, in the A549 
cells were scratch for 24 hours (Fig 3.7. 1 ± 0.3 Vs 0.8 ± 1.3 n=3). There was also a 0.9-fold 
increase in the gene expression of C11orf30, in the A549 cells were scratch for 24 hours (Fig 
3.7. 1 ± 0.2 Vs 0.9 ± 1.2 n=3). However, when the BEAS-2B cells were first treated with TGF-
β1 for 24 hours and a scratch was generated the gene expression of C11orf30, increased 2.2-fold 
(Fig.3.7. 1 ± 1.3 Vs 2.2 ± 2.3 n=3). When this treatment was repeated on the A549 cells the gene 































Figure 3.7: RNA gene expression of C11orf30 during early induced EMT conditions of cells 
seeded on matrigel. Experiment was replicated n=3 
4.4. Cellular location of C11orf30 in BEAS-2B and A549 under different EMT-inducing 
conditions 
Previous research has shown that the protein product of C11orf30, EMSY, is exclusively nuclear 
in breast cancer specimens (Hughes-Davies et al., 2003). However, the cellular localisation of 
EMSY, in lung epithelial cells is not known. Immunofluorescent cell imaging showed that EMSY 
was nuclear in 19.8% of the BEAS-2B cells when cells were starved with 1% FCS for 24 hours 
(Fig.3.8.A and 12). However, treating BEAS-2B cells with TGF-β1 for 24 hours exhibited that 
93.3% of EMSY relocated to the perinuclear site of the cells (Fig.3.8. B and 12). In the A549 cell 
line, the staining revealed that, 11.11% of all cells exhibited nuclear localisation of EMSY, however 
88.89% of EMSY was located at the perinuclear of the cell when cells were starved with 1% FCS 
for 24 hours (Fig.3.11 A and 3.14). When TGF-β1 was added to induce early EMT, 98.5% of cells 
exhibited perinuclear location of EMSY. (Fig. 3.11. B and 3.14). When comparing this results with 
the localisation of EMSY in BEAS-2B cells, it shows that during TGF-β1 treatment both cell lines 
exhibited perinuclear location of EMSY. However, the results also showed that EMSY is localised 
in the nucleus of the BEAS-2B cells when the cells were starved for 24 hours. In the A549 cells 
EMSY was located nuclear and perinuclear when the cells were starved for 24 hours. Results 
presented here have shown that 19.8% of BEAS-2B cells exhibited nuclear EMSY where as 11.1% 
of A549 cells exhibited nuclear EMSY when the cells were starved for 24 hours. when TGF-β1 to 
both cell lines EMSY relocated into the cytoplasm.    
 
Having established that growth of A549 and BEAS-2B cells on matrigel and treatment with TGF-
β1 increased the expression of the EMT marker CDH2, as well as cell invasion, we conclude that 
TGF-β1-induced EMT resulted in the export of EMSY from the nucleus. Given this, the next step 
was to observe the cellular localisation of EMSY during cell migration. To test this, cells were 
seeded on matrigel and a scratch was introduced. Two or twenty-four hours after the scratch was 





























showed that the expression of EMSY increased greatly, and that 64.3% of EMSY was found to be in 
the nucleus of the BEAS-2B cells, after a 2hr scratch was generated (Fig. 3.9 and 3.12). Addition of 
TGF-β1 to the cells 24 hours prior to scratching of the monolayer showed the expression of EMSY 
declined and nuclear EMSY started to relocate into the perinuclear site of the cells. This can be 
seen as only 23.1% of EMSY was found to be nuclear in the cells. This is a 40.3% decline, 
compared to when a wound was generated (Fig 3.10. and 3.12). A scratch time point assay was 
performed and it revealed that after 24 hours 70% of EMSY relocated into the perinucleus of the 
BEAS-2B cells (Figure 3.13). In comparison, when a scratch was generated in the A549 cells, 
EMSY localization was perinuclear. It must be stated that there were some nuclear EMSY present 
(Fig. 3.11. C and 3.14). This suggests that EMSY was exported from the nucleus (Fig.3.14 and 
Fig.3.15). When TGF-β1 was added for twenty-four-hours before the wound was generated, 
immunofluorescence cell imaging revealed that EMSY was nuclear and perinuclear in A549 cells 
(Fig. 3.11. D and 3.14). This result was similar to what was observed when a wound was generated 
in A549 cells which had no TGF-β1 stimulation. 
 
Western blot analyses was carried out on BEAS-2B cells to confirmed that EMSY is nuclear during 
different EMT conditions, as seen on the immunofluorescence images showed in Figure 3.8. The 
western blot showed that when the BEAS-2B cells were starved for 24 hours, EMSY was nuclear. 
However, when TGF-β1 was added to the cells for 24 hours, no nuclear EMSY was observed. 
When a 2 hour scratch was generated, or when cells were treated with TGF-β1 for 24 hours first, 
and then a 2 hour scratch was generated, the western blots showed nuclear EMSY protein under 
both conditions (Figure 3.16). The results showed the EMSY moved cellular location in BEAS-
2B cells under different EMT conditions. 
 
 









A)                                                                                       B)  
Figure 3.8: Immunofluorescence analysis were performed with indicated antibody on BEAS-2B 






































Figure 3.9: Immunofluorescence analysis were performed with indicated antibody on BEAS-2B 

















































Figure 3.10: Immunofluorescence analysis were performed with indicated antibody on BEAS-2B 

















2hr Scratch + TGF-β1 








































C)                                                         D) 
Figure 3.11: Immunofluorescence analysis were performed with indicated antibody on A549 cells 
after cells were A) starved for 24hr, B) starved and treated with TGF-β1 for 24hr, C) stared for 




































24hr starvation TGF-β1 




Figure 3.12: Percentage of cells exhibited nuclear EMSY in BEAS-2B cells VS A549 during 




Figure 3.13: Percentage of cells exhibited nuclear EMSY during a 2 hour scratch VS a 24 hour 
































































Figure 3.14: Percentage of cells exhibited nuclear EMSY during different scratch periods in A549 
























































































Figure 3.15: Immunofluorescence analysis were performed with indicated antibody on A549 cells 


















































144kDa Nuclear EMSY 
13kDa                              Claudine  
Figure 3.16: Western blot showing nuclear EMSY protein in BEAS-2B cells, when cells were 
starved for 24 hours, scratched for 2 hours or treated with TGF-β1 and scratched for 2 hours.    
 
4.5. Flow cytometry data flow cytometry showed a change in the expression of EMSY 
The expression of EMSY was next assessed using flow cytometry analysis of whole cells and 
isolated nuclei. When the BEAS-2B cells were starved for 24 hours, and whole cell staining was 
carried out for EMSY, the flow data showed that 34.4% of the cells were positive for EMSY 
expression (Fig.3.17 B). Addition of TGF-β1 for 24 hours resulted in only 23.8% of the cells 
detected as positive for EMSY expression (Fig.3.17 C). When a confluent BEAS-2B monolayer 
was treated with a 2 hour scratch, 33.7% showed expression for EMSY (Fig.3.17 D). However, 
when the BEAS-2B cells were scratched and treated with TGF-β1 23% of the cells were positive 
for EMSY expression (Fig.3.17 E). This is a 10.3% decrease in positive EMSY expression 
compared to when cells were scratch. This once again shows that treating the cells with TGF-β1 
lowers the protein level of EMSY in the BEAS-2B cells. 
 






















































Figure 3.17. Flow cytometry analysis of EMSY expression in BEAS-2B cells. Shown are dot-plots 
for EMSY (C11orf30-FITC) and side-scatter (SSC). Shown are: A. cells labelled only with secondary 
Alexafluor-488 antibody; B-D: cells labelled with anti-EMSY and secondary Alexafluor-488 
antibody. Gates were set based on cells labelled only with secondary Alexafluor-488 antibody.  Cell 
culture conditions are: A.  1%FCS; B. 1%FCS; C. 1%FCS plus TGF-β1; D. 1%FCS plus 2 hours 
scratch E. 1%FCS plus 2 plus TGF-β1.   
Together the whole stain flow data and the immunofluorescent staining images have shown that the 
total amount of EMSY decreases in response to TGF-β1. To quantify nuclear EMSY, nuclei were 
isolated from treated cells and labelled with an anti-EMSY antibody. The flow cytometry results 
showed that 10.5% of nuclei isolated from cells were cultured for 24 hours in 1% FCS showed a 
positive anti-EMSY signal (Fig.3.18. A). In a population of nuclei isolated from cells treated with 
TGF-β1 for 24 hours, only 3.1% of the nuclei exhibited a positive EMSY signal (Fig.3.18. B). The 
flow data also showed that nuclei isolated from cells that were scratched for 2 hours exhibited 5.4% 
positive EMSY signal (Fig.3.18. C) and cells that were treated with TGF-β1, for 24 hours and 
scratched for 2 hours, also showed a 7% positive EMSY signal (Fig.3.18. D) Overall these results 
indicate that EMSY is nuclear during migration EMT in BEAS-2B cells and therefore may play a 
role in regulating the gene expression of EMT genes, during migratory EMT.             



















Figure 3.18. Flow cytometry analysis of EMSY expression nuclear BEAS-2B cells. Shown are dot-
plots for EMSY (C11orf30-FITC) and side-scatter (SSC). Shown are: A. cells labelled only with 
secondary Alexafluor-488 antibody; B-D: cells labelled with anti-EMSY and secondary Alexafluor-
488 antibody. Gates were set based on cells labelled only with secondary Alexafluor-488 antibody.  
Cell culture conditions are: A.  1%FCS; B. 1%FCS plus TGF-β1; C. 1%FCS plus 2 hours scratch D. 
1%FCS plus 2 plus TGF-β1.   
 
4.6. The PI3K/Akt pathway regulates the cellular location of EMSY in BEAS-2B cells 
It has been proposed that the P13K/Akt pathway regulates EMSY (Ezell et al, 2012). Given that the 
PI3K pathway is also activated during TGF-β1 induced EMT (Tian et al., 2015a) this led to an 
investigation into whether the PI3K/Akt pathway regulates the cellular localisation of EMSY in 
BEAS-2B cells in response to TGF-β1 treatment. Immunofluorescence imaging showed that when 
the PI3K/Akt pathway was active and the BEAS-2B cells were starved with 1% FCS for 24 hours, 
68.8% of the cells had nuclear EMSY present. When the PI3K/Akt pathway was chemically 
inhibited with LY294002 for 24 hours, only 1.5% of the cells had nuclear EMSY protein present in 
the cells. However, there was a great amount of EMSY protein expression present in the cytoplasmic 
part of the cells when the pathway was inhibited. When the BEAS-2B cells were treated with TGF- 
β1 and the PI3K/Akt pathway was chemically inhibited with LY294002 for 24 hours, 50% of cells 
had nuclear EMSY (Fig 3.19. and 3.20). This indicates that the signaling pathway PI3K/Akt needs 
to be activate in BEAS-2B cells to be able to phosphorylate EMSY, so it can stay in the nucleus in 




24hr Starvation + DMSO          24hr LY294002 24hr                      LY294002 + TGF- β1 
Figure 3.19: Immunofluorescence analysis were performed with indicated antibody on BEAS-2B 
cells after cells were; starved for 24hr, chemically inhibited with LY294002 for 24hr and treated 















Figure 3.20: Percentage of nuclear EMSY after BEAS-2B cells were; starved for 24hr, chemically 
inhibited with LY294002 for 24hr and treated with TGF-β1 and chemically inhibited with LY294002 
for 24hr. 
 
4.7. EMSY and KDM5A co-localizes in BEAS-2B VS A549 under different EMT conditions  
Previous work has shown that KDM5A and C11orf30 (Larue and Bellacosa, 2005, Varier et al., 2016) 
to repress the expression of miR-31. The repression of miR-31 enhances the invasion and migration 
capacity of tumours in breast cancer. Given this, experiments were conducted to establish whether 
EMSY and KDM5A shows a similar pattern of cellular localisation in response to TGF-β1and 
migration EMT, in BEAS-2B and A549 cells. 
Publications have shown that KDM5A is nuclear in different cell lines (Spangle et al., 2016). In 
agreement with these observations, immunofluorescence imaging showed that 68.8% of BEAS-2B cells 
exhibited nuclear KDM5A (Figure.3.21. A). However, when TGF-β1 was added to these BEAS-2B 
cells for 24 hours, only 22.4% of the cells exhibited nuclear KDM5A (Figure.3.21. B). This decline 
in KDM5A was also observed for EMSY, when BEAS-2B cells were treated with TGF-β1, for 24 
hours (Figure.3.8. B). This may suggest that TGF-β1 EMT causes EMSY and KDM5A to be exported 
out of the nucleus. In comparison to these results, when A549 cells were starved with 1% FCS for 24 
hours 94.1% of A549 cell exhibited cytoplasmic KDM5A. (Figure3.22. A). Addition of TGF-β1 for 
24 hours, 86.5% of cells displayed cytoplasmic KDM5A (Figure.3.22 B).   
 
As previously stated, EMT plays a vital role in wound healing and pervious results have shown that 
EMSY relocates into the nucleus, when a scratch is generated in the BEAS-2B cell culture models 
(Fig.3.9). Due to prior stains demonstrating that EMSY and KDM5A showed a similar cellular 
distribution in the presence and absence of TGF-β1, immunofluorescent staining was carried out to 































cells following a 2 hour scratch showed, 76.6% of cells exhibited nuclear localization of KDM5A 
(Fig.3.21. C) The results also showed that nuclear KDM5A was more concentrated where the wound 
was generated, than when it was further away from the wound site (Fig.3.23 and 3.24.) However, when 
TGF-β1 was added for 24 hours before a scratch was done, 89.2% of cells exhibited nucleus KDM5A 
in the BEAS-2B cells. It did appear that the nuclear KDM5A started to relocate into the cytoplasm and 
accumulate at the adhesion junctions of the cell (Fig.3.21. D). This was similarly observed for EMSY 
when the BEAS-2B cells treated with TGFβ1and scratched.   
When a 2 hour scratch was done in A549 cell culture models, immunofluorescence staining showed 
that 98.2% of cells exhibited cytoplasmic KDM5A (Fig.3.22. C). When TGF-β1 was added for 24 
hours before a scratch was generated in the A549 cells, 99.1% of cells exhibited cytoplasmic (Fig.3.22. 
D). This was similar observed for EMSY under this condition (Figure3.10). When TGF-β1 was added 
for 24 hours before a scratch was generated KDM5A remained in the cytoplasm. A similar observation 
was made for C11orf30, under this condition. This may suggest that TGF-β1 stimulus does not play a 










































  C)                                                          D) 
Figure 3.21: Immunofluorescence analysis were performed with indicated antibody on BEAS-2B 
cells after cells were A) starved for 24hr, B) starved and treated with TGF-β1 for 24hr, C) stared for 

















































24hr starvation TGF-β1 





















C)                                                           D)                
Figure 3.22: Immunofluorescence analysis were performed with indicated antibody on A549 cells 
after cells were A) starved for 24hr, B) starved and treated with TGF-β1 for 24hr, C) stared for 24hrs 













































24hr starvation TGF-β1 




Figure 3.23: Percent of nuclear KDM5A present in BEAS-2B cell near the wound area (1) versus and 
an area further away from the wound site (2).   
 
A)     B) 
Figure 3.24: Immunofluorescence analysis of nuclear KDM5A in BEAS-2B cell at the scratch site 


































































4.8. KDM5A binds to the C11orf30 promoter during early EMT events 
Previous immunofluorescence analysis conveyed that that EMSY and KDM5A show a similar 
localization throughout the cell in response to different EMT treatments. Due to these observations, a 
KDM5A ChIP was undertaken to explore KDM5A binds to the promoter region of C11orf30. Results 
from an anti-KDM5A ChIP experiment showed that, during both TGF-β1 induced EMT and migration 
EMT, KDM5A bound to the C11orf30 promoter. The data showed that there was a 3.9-fold enrichment 
of KDM5A at the promoter site of C11orf30, when the BEAS-2B cells were treated with TGF-β1 for 
24 hours. The data also displayed that there was a 2.7-fold enrichment of KDM5A at the promoter site 
of C11orf30, when a 2 hour wound was introduced through scratching the monolayer of the BEAS-2B 
cells were. Due to these results, the ChIP experiment was expanded to observe what happens to 
C11orf30 and KDM5A binding when both EMT events occur at the same time. The results showed that 
when the BEAS-2B cells were treated for 24 hours with TGF-β1 and a wound was generated at 2 and 
24 hours, the binding of C11orf30 to KDM5A increased. There was a 4.4-fold enrichment of KDM5A 
at the promoter site of C11orf30, when cells were treated with TGF-β1 and scratched for 2 hours. 
However, this enrichment increased to 6.5-fold when cells were treated and scratched for 24 hours. 
Overall the ChIP data indicated that C11orf30 binds to KDM5A, during early EMT events in BEAS-2B 
cells (Fig. 3.25). There is no what is set value which is consider a significant fold-enrichment value for 
chip in the literature.  A paper state that a 2-fold to 4-fold enrichment is significant (Fan et al., 2008). 
For this study a significant fold-enrichment value will be 4 or more. If 4-fold enrichment is considered 
significant then the KDM5A Chip data showed that C11orf30 binds to KDM5A when BEAS-2B cells 
were treated with TGF-β1 or scratched and treated with TGF-β, because under these conditions there 




Figure 3.25: Fold enrichment of KDM5A binding to the promoter region of C11orf30 in BEAS-2B 
cells were treated with various stimulus to induce EMT.   
4.9. EMSY binds to the CpG islands at the promoter site of certain epithelial and 
mesenchymal regulatory genes, during early EMT in BEAS-2B cells 
Various studies have stated that EMSY binds to other genes to promote invasion of cancer cells (Rana 
et al., 2011, Vire et al., 2014). Results presented here have shown that EMSY relocated into the 
nucleus, when a wound was generated in the BEAS-2B cell culture models (Figure.3.8 C). Thus, 
indicating it may play a role in regulating transcription during wound closure in healthy lung 
epithelial cells. Based on these observations, EMSY chromatin immunoprecipitation (ChIP) assays 
were performed in BEAS-2B cells, to observe if EMSY binds to the CpG islands at the promoter site 
of epithelial and mesenchymal regulatory genes, during TGF-β1 and wound closure EMT.  
CDH1: 
ChIP analyses indicated that there was a 26-fold enrichment of EMSY at the CpG promoter region 
of CDH1, when BEAS-2B cells were starved for 24 hours in 1% FCS (Fig.3.26). Previous RNA 
gene expression results in BEAS-2B cells, showed a 1.7-fold increase in CDH1 gene expression, 
and a 0.7-fold increase in C11orf30 gene expression, when BEAS-2B cells were starved for 24 hours 
(Fig.3.27). Flow cytometry data showed that 20% of BEAS-2B nuclei showed nuclear localization 
of EMSY under this condition This may prove that C11orf30 positively regulates the gene 
expression of CDH1, when BEAS-2B cells are being starved. The ChIP data also revealed that there 
was 4-fold enrichment of EMSY at the CpG promoter site of CDH1, when a 24 hour scratch was 
generated. This may indicate that there is moderately weak binding of EMSY to CDH1 promoter, 

























Figure.3.26: Fold enrichment of EMSY binding to the CpG promoter region of CDH1 in BEAS-
2B cells. Experiment was replicated n=3 and the data are shown as mean ± SEM. 
 
Figure 3.27:  RNA gene expression of C11orf30 and CDH1 in BEAS-2B cells, when cells were 
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ChIP analyses indicated that there was a no fold-enrichment of EMSY at the CpG promoter region 
of CDH2, when BEAS-2B cells were treated with various EMT stimulus. Thus, showing EMSY 
does not bind to CDH2 when BEAS-2B cells are undergoing partial EMT (Fig.3.28).   
 
Figure.3.28: Fold enrichment of EMSY binding to the CpG promoter region of CDH1 in BEAS-
2B cells. Experiment was replicated n=3 and the data are shown as mean ± SEM. 
Zeb:  
The hypothesis is that EMSY binds to CpG islands of promoters involved in EMT. The 
mesenchymal gene Zeb has a CpG island and it is a transcriptional factor that is active during 
cancer progression EMT (Xiao and He, 2010). The ChIP data also showed a 2.2-fold enrichment 
of EMSY, at the CpG promoter site of the mesenchymal regulator gene Zeb, when the BEAS-2B 
cells were starved for 24 hours. However, the data also revealed that there was a 1.1-fold 
enrichment of C11orf30 at the promoter region of Zeb, when the BEAS-2B cells were starved, 
scratched, and treated with TGF-β1 for 24 hours (Fig.3.29). A gene expression assay was 
performed and demonstrated that the gene expression of Zeb does not change when cells are 
starved for 24 hours or when the BEAS-2B cells are starved, scratched, and treated with TGF-β1 
for 24 hours (Fig.3.30). Together these results illustrate that there is no significant binding of 
EMSY to the CpG promoter of Zeb, due to the low percentage enrichment values in Figure 3.29 











1% B1 10% B1 1% 24 hr
Scratch
1% 2h S +
B1 EMSY
1% 24h S +
B1 EMSY















Figure.3.29: Fold enrichment of EMSY binding to the CpG promoter region of Zeb in BEAS-2B 
cells. Experiment was replicated n=3 and the data are shown as mean ± SEM. 
Figure.3.30: RNA gene expression of Zeb in BEAS-2B cell under different EMT conditions.   
FoxA2: 
To further investigate whether EMSY binds to the CpG promoter region of epithelial and 
mesenchymal regulatory genes, during early EMT, a ChIP was undertaken to observe if C11orf30 
binds to a CpG island located several Kilo bases (Kb) away from the promoter region of FoxA2. 
FoxA2 is a mesenchymal transcription factor that is active during EMT. The CpG island of 
interest does co-localisation with epigenetic marks such as H3k4me3 and H3k4me1 (Fig.3.31). 
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gene expression of genes in differentiated tissues. Researchers have shown that FoxA2 can open 
compacted chromatin for other proteins by interacting with the nucleosomal core. The Chip data 
revealed that there was a 3-fold enrichment of EMSY at the this CpG region, when the BEAS-
2B cells were starved for 24 hours with 1% FCS. However more noteworthy, was that there was 
a 11.1-fold enrichment of EMSY at this CpG island when the cells were treated with TGF-β1 for 
24 hours and a 2 hour scratch was generated (Fig.3.31). The standard deviation for this treatment 
was relatively high but, it must be stated to generation a scratch which is identical every time is 
almost impossible. This can be seen as throughout the results, as all the data showing scratches 
have high standard errors bars. If this issue is taken into account this result may demonstrate that 
EMSY is able to bind to bind to the CpG island near the FOXA2 promoter during migration EMT 
in BEAS-2B cells.  
 
    
Figure.3.31: Fold enrichment of EMSY binding to the CpG region several Kb away from the 
promoter site of FoxA2 in BEAS-2B cells were treated with various stimulus. Experiment was 
replicated n=3 and data are shown as mean ± SEM. 
4.10. A putative enhancer identified genome wide association studies (GWAS) 
between C11orf30 and LRRC32 does not interact with EMSY 
Various genome-wide association studies (GWAS) have suggested that there are four SNPs 
located between C11orf30 and LRRC32 (rs7130588, rs2508746, rs10899234, and rs6592657) that 
are in a region that includes a possible enhancer that is associated with specific epigenetic marks, 
such as Histone 3mono-methylation of lysine 4 (H3K4Me1) and acetylation of lysine 27 that 
identify active enhancers (Figure.3.32). The question remains whether the locus identified in 
GWAS is able to regulates C11orf30 gene expression during EMT or, is it the PI3K/AKT pathway 











1% B1 10% B1 1% 24 hr
Scratch
1% 2h S + B1
EMSY
1% 24h S +
B1 EMSY














pathway is able to phosphorylate EMSY, which causes EMSY to stay into the nucleus of the 
BEAS-2B cells (Fig.3.19). When the pathway was inhibited no nuclear EMSY was observed in 
the BEAS-2B cells. Flow cytometry and immunofluorescent imaging showed that TGF-β1stimuli 
causes EMSY to be exported out of the nucleus (Fig.3.18).          
 
 
Figure.3.32: In silico data using ChIP and SNPs to illustrate in a region between C11orf30 and 
LRRC32 that may be a possible enhancer. The locus is located in a region marked with epigenetic 
markers such as H3k4me3 and H3k4me1. High methyl levels of H3k4me3 and H3k4me1indicated 
active enhancers.    
To establish whether there was an alleged C11orf30 enhancer, 3 independent chromatin 
immunoprecipitation (ChIP) assays were employed. It must be stated that all the ChIP assays were 
performed in BEAS-2B cells. In total 8 different conditions (1% FCS, 10% FCS, 1% TGF-β1, 1% 
FCS 2 hour scratch, 10% FCS 2 hour scratch, 10% FCS 2 hour scratch + TFGB1, 10% FCS 2 hour 
scratch + TGF β1, 1% FCS 24 hour scratch + TGF- β1, 10% FCS 24 hour scratch + TGF- β1) 
were used to test for enhancer activity. All three ChIP experiment displayed high level fold 
enrichment of H3K4me3 compared to low levels of fold enrichment of H3K4me1 for most of the 
conditions. Thus, indicating that there is no enhancer under these conditions regulating C11orf30 
gene expression. During 1% FCS, there was a 1.3 H3K4me1 fold enrichment, as well as, a 0.44 
and 0.75 H3K4me1 fold enrichment during 1% FCS 2 hour scratch and 1% FCS 2 hour scratch + 
24 hour TGFB1 (Fig.3.33). Though there were an increase in H3k4me1 binding under these 3 
conditions they were not significant enough to indicate that a possible enhancer is located in this 
region. Thus, indicates that the putative enhancer mentioned in the GWAS, is not interacting with 




Figure.3.33: BEAS-2B cells were treated with TGF-β1or scratch at different time points, or 
treated and scratch. After treatments ChIP was performed on the genes indicated in the figure 
legend.     
To further test for a passible putative enhancer near C11orf30 a luciferase PGL3-2.5kb 
C11orf30_LUC promoter vector was designed and constructed by Kate. This plasmid contained 
the 2.5Kb region between C11orf30 and LRRC32 which in silico data indicated might be an 
enhancer. Relative luciferase activity was carried out in both BEAS-2B and A549 cells and little 
to none bioluminescence was detected in either cell line (Fig.3.34). Overall the data has shown 
that it is the P13k/Akt pathway and TGF-β1 that regulates the cellular location of EMSY during 
EMT in lung cells. The data showed that EMSY is able to regulate the EMT process in BEAS-2B 






























































Figure.3.34: BEAS-2B and A549 cells were treated under different conditions to induce EMT, 
after which luciferase assays were performed on the cells and luminescence was measured to look 
for any enhancer activity.  Thus, indicating no enhancer regulating the gene expression of 
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The C11orf30 gene is part of a locus identified by multiple GWAS that is associated with 
inflammatory illnesses such as asthma and atopic dermatitis (Bønnelykke et al., 2013, Esparza-
Gordillo et al., 2009). Studies on breast cancer show a correlation with cancer and amplification 
of C11orf30, suggesting an involvement of this gene in epithelial cancers. However, it is unclear 
how EMSY, the protein product of C11orf30, contributes to cancer. The goal of this research 
project was to investigate the expression, function and location of C11orf30 and EMSY in the non-
cancerous human bronchial epithelial cell line BEAS-2B, and to compare this to C11orf30 and 
EMSY expression in cancerous bronchial epithelial cell line, A549, in the context of EMT. The 
research question was extended to test if EMSY is a direct transcriptional regulator of CDH1 and 
CDH2, encoding E- and N-cadherin respectively, both of which are involved in the early stages of 
epithelial–mesenchymal transition (EMT).   
The A549 cell line is derived from a patient with lung cancer and carries a high number of 
mutations in genes that control cell adhesion and proliferation (Soto-Pantoja et al., 2009). In 
contrast, the BEAS-2B cell line is an immortalized cell line, derived from healthy lung tissue 
(Stewart et al., 2012). The use of these two cell lines provided an opportunity to study the cellular 
localization and expression of EMSY in the context of EMT. It was found that culturing the cell 
lines on the basement membrane extract Matrigel improved result reproducibility and produced 
gene expression patterns more reminiscent of TGF-β induced EMT.  
While treatment with TGF-β1 resulted in significant increases in CDH2 expression relative to 
CDH1 expression in both A549 and BEAS-2B cells, the magnitude of the increase of CDH2 
expression was much greater in A549 cells. Studies have shown that an increased CDH2 and 
decreased CDH1 expression result in suppression of the cell-cell adhesion and cause cells to take 
on an invasive phenotype (Wong and Gumbiner, 2003). Therefore, it can be concluded that EMT 
was induced in both A549 and BEAS-2B cells in response to TGF-β1. Similarly, results from 
invasion experiments showed that both cell lines became invasive when treated with TGF-β1, 
although the induction of cell invasion was several folds higher in A549 cells. This is expected as 
A549 cells are from a lung cancerous cell line, which are phenotypically more invasive compared 
to non-cancerous lung cells (Chang et al., 2012). Therefore, it could be concluded that A549 cells 
are highly responsive to TGF-β1, as seen by changes in CDH2 gene expression and invasion. 
BEAS-2B cells also respond to TGF-β1, but to a lesser degree. A549 cells have mutations in their 
epidermal growth factor receptor (EGFR), and FAK signaling pathways such as KRAS 
(Cancergenome). This means these cells are more invasive and more likely to undergo EMT. The 
results of this thesis showed that EMSY was localized in the nucleus in in the non-cancerous 
BEAS-2B cell line under non-EMT conditions. This may indicate that EMSY contributes to 
maintaining epithelial homeostasis in normal lung cells. In response to TGF-β1 there was export 
of EMSY from the nucleus. Results showed that the cancerous A549 cells had less nuclear EMSY 
when compared to BEAS-2B cells, suggesting that genetic changes in the A549 cells may 
dysregulate the cellular localization of EMSY. Gene expression data showed that C11orf30 gene 
expression did not change in BEAS-2B or A549 cells in response to treatment with TGF-β1. Hence 
it can be concluded that during TGF-β1-induced invasion, there is a TGF-β1-dependent relocation 
of EMSY from the nucleus to the cytoplasm.  
pg. 59 
 
Moreover, when monolayer cultures of BEAS-2B cells were scratched to induce cell migration the 
cells exhibited nuclear EMSY.  In these experiments, RNA gene expression data showed there was 
no change in CDH2 expression, but there was a decrease in CDH1 expression, when BEAS-2B 
cells were scratched for 24 hours. Enhanced migration in immortalized human mammary epithelial 
cells (HMEC) is not a phenotypic requirement of EMT, with cell migration occurring independent 
from invasion, whereas invasion is dependent on migration during carcinoma-associated EMT 
(Schaeffer et al., 2014). The study also indicates that a decrease in cell-cell adhesion may 
contribute to an increase in epithelial cell migration in HMEC cells. This study also shows an 
increase in epidermal growth factor receptor (EGFR) expression that drives the migration of 
HMEC cells (Schaeffer et al., 2014). In this regard, ChIP results presented in this thesis showed a 
decrease in EMSY binding to the CDH1 promoter at 10% FCS. This may indicate that EMSY 
binding to CDH1 is correlated with growth-factor-dependent changes that might promote EMT in 
BEAS-2B cells. It is of interest to note that the EGFR gene has activating mutations (Gazdar, 2009)  
this could explain the greater responsiveness of A549 cells to TGF-β1.  Future work would focus 
on undertaking a EMSY ChIP in A549 cells to observe if EMSY binding to CDH1 differs in A549 
cells compared to BEAS-2B cells.  
Immunofluorescence analysis showed increased nuclear EMSY at the scratch boundary in BEAS-
2B cells, including in cells treated with TGF-β1 that was shown to result in nuclear export of 
EMSY. This suggests that at areas of damage to the cell monolayer as a result of scratching, EMSY 
was located in the nucleus, despite the addition of TGF-β1. This suggests that nuclear EMSY is 
required for repair and migration associated with the scratch assay. Damage to human small airway 
epithelial cells (SAEC) increase in Wnt-induced secreted protein (WISP) 1 expression in alveolar 
type (AT) II cells (Zemans et al., 2013). This increase induced epithelial-mesenchymal transition 
(EMT), in the SAEC cells, with more pronounced WISP1 expression at the wound. WISP1 is a 
protein involved in cell proliferation, migration and survival (Zemans et al., 2013), demonstrating 
that re-localisation of cellular proteins occurs to regulate wound healing in lung epithelial cells. 
Results presented in this thesis support a correlation between the nuclear localization of in BEAS-
2B cells to enable cells to migrate and heal scratch-induced wounds. In the absence of damage to 
an epithelial layer, EMSY is also localized in the nucleus, suggesting a role associated with 
maintaining a stable epithelial barrier. This is supported by results that that during invasive EMT 
in BEAS-2B cells, EMSY is repressed and relocates into the cytoplasm. As the RNA expression 
of EMSY did not change during either TGF-β1 induced EMT or scratching, if EMSY is to have a 
role in epithelial cells it must involve cellular redistribution of EMSY.  
The induction of EMT by TGF-β1 is associated with the activation of the PI3K/Akt signaling 
pathway (Bakin et al., 2000). TGF-β1 activates the PI3K/Akt pathway during EMT through the 
RhoA signaling pathway, which leads to tumour progression in various cancer cell lines. TGF-β1 
can also regulate the expression of EGF and induce the intracellular localization of EGFR, which 
leads to the activation of the PI3K/Akt pathway (Xu et al., 2015). During viral infection, the 
P13K/Akt pathway phosphorylates EMSY to relieve EMSY repression of interferon stimulating 
genes. (Tian et al., 2015b). In the results presented in this thesis it was shown that when the 
PI3K/Akt pathway is active in BEAS-2B cells, EMSY is nuclear in the cells. However, when the 
pathway was chemically inhibited none of the BEAS-2B cells showed nuclear EMSY. When the 
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cells were treated with TGF-β1 and the PI3K/Akt pathway was inhibited EMSY, nuclear EMSY 
was observed in the cells. Therefore, it was concluded that in BEAS-2B cells EMSY cellular 
localisation was regulated by the PI3K/Akt pathway. Therefore, it is suggested that in the BEAS-
2B cell line activation of the PI3K/Akt pathway phosphorylates EMSY, causing EMSY to be 
exported out of the nucleus.  
Protein-protein interaction between EMSY and KDM5A, have been identified in the breast cancer 
cell line, MCF7. KDM5A is a histone lysine demethylase, that contains a PHD finger that directly 
binds H3K4me3 (Varier et al., 2016a). Chromatin immunoprecipitation (ChIP) analyses in this 
project, showed that KDM5A binds to C11orf30 when BEAS-2B cells were treated with TGF-β1. 
In addition, immunostaining showed that both KDM5A and EMSY relocated into the cytoplasm, 
when BEAS-2B cells were treated with TGF-β1. Therefore, it can be concluded that during TGF-
β1 induced EMT, KDM5A binds to the promoter of C11orf30.   
It is known that CDH1 gene expression declines and CDH2 gene expression increases when cells 
undergo EMT and become invasive (Yan et al., 2010). ChIP analyses in the project showed that 
EMSY binds to the CpG promoter of CDH1 when BEAS-2B cells are starved with 1% FCS. The 
RNA gene expression data showed the level of CDH1 expression in BEAS-2B cells in 1%FCS is 
2-fold higher than BEAS-2B cells grown in 10% serum. Taken together, there is a correlation 
between increased CDH1 expression and maximal binding of EMSY to the CDH1 promoter in 
BEAS-2B cells cultured in 1% FCS, suggesting that EMSY activated CDH1. Conversely, in 
BEAS-2B cells cultured in 10% FCS, there is decreased association of EMSY with the CDH1 
promoter and this is accompanied by a lower level of CDH1 gene expression. There was also an 
increase in EMSY binding to the CDH1 promoter when a BEAS-2B cell monolayer was scratched 
and analyzed 24 hours later. The magnitude of EMSY binding after this scratch was smaller in 
comparison to cells cultured in 1% FCS. Immunostaining results showed that when the BEAS-2B 
cells were scratched, nuclear EMSY was concentrated along the scratch boundary and declined in 
cells distant from the scratch. This might account for why there was smaller magnitude of EMSY 
binding to CDH1 after BEAS-2B cells were scratch, relative to cells cultured in 1% FCS. 
Consistent with this idea, the RNA gene expression data showed a decrease in CDH1 gene 
expression, 24 hours after scratching the cell monolayer.  
5.1. Conclusion    
The project’s aim was to investigate whether C11orf30 plays or role during EMT in BEAS-2B, or 
A549 cells. The project showed that EMSY relocated into the cytoplasm during TGF- β1 induced 
EMT in BEAS-2B cells. It also showed that during TGF- β1 induced EMT in BEAS-2B cells, 
KDM5A binds to the C11orf30 promoter. The project also showed that during migration in BEAS-
2B cells EMSY is located in the nucleus of the cells, where it is able to repress the gene expression 
of CDH1. It also showed that in healthy epithelial cells, EMSY is able to positively regulate CDH1 
gene expression. Ultimately the project showed that EMSY is able to regulate TGF-β1 induced 





5.2. Limitations and Future work 
Due to time constraints around this project, the results, while consistent, do need to be replicated 
and verified. Another limitation is the cells heterogeneity which, allows for variation to occur 
within the results.  
Future work will focus on testing for other EMT regulated genes, to observe if EMSY regulates 
those genes during migration or TGF- β1 EMT. Chromatin immunoprecipitation (ChIP) samples 
will also be send of for ChIP-sequencing. This will allow for parallel DNA sequencing to be used 
to identify the binding sites of DNA-associated proteins involved in EMT. ChIP-sequencing will 
also be used to identify EMSY related genes. Recombinant EMSY proteins will also be used to 
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9.1.  Flow cytometry FSC/SSC gates  
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All 51,692 424 100.00% 100.00% 689,055.20 130,342.20 247.92% 398.88%   
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All 64,461 546 100.00% 100.00% 513,522.34 129,834.16 242.07% 419.72%   
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All 64,294 554 100.00% 100.00% 2,848,788.09 287,902.50 127.48% 208.47%   
E1 22,390 193 34.82% 34.82% 6,912,678.23 552,792.97 32.19% 42.90%   
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All 45,510 303 100.00% 100.00% 2,151,105.42 217,328.63 163.25% 249.00%   
E1 10,969 73 24.10% 24.10% 7,422,556.63 584,852.22 32.06% 40.72%   
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All 50,144 432 100.00% 100.00% 306,311.53 87,513.01 208.10% 460.32%   
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All 49,901 396 100.00% 100.00% 286,450.27 76,165.43 227.81% 577.86%   
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All 38,196 101 100.00% 100.00% 274,786.92 69,896.07 190.56% 523.85%   
E1 20,135 53 52.71% 52.71% 134,886.85 19,474.05 38.23% 63.12%   
pg. 73 
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All 44,999 125 100.00% 100.00% 290,180.00 70,075.00 211.57% 470.65%   
E1 23,416 65 52.04% 52.04% 136,969.22 19,753.11 38.06% 62.04%   
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9.2. Original Western Blots 
 
EMSY and TGF-B2 Western Blot: 
  
 
Claudine Western blot: 
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